Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
By Fortunato Ciardiello, R. Caputo, R. Bianco, V. Damiano, G. Fontanini, S. Cuccato, S. Placido, A. Bianco, G. Tortora. Clinical Cancer Research, 2001
662 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/bd19813d6779d0ac18906fbf9260626be53270f9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- S. Wedge
- A. Wakeling
- G. Tortora
- S. P. Guy
- J. Kendrew
- Fortunato Ciardiello
- J. Woodburn
- L. Hennequin
Citations in the corpus
- A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. (2001, background): “A recent study has demonstrated that ZD1839 blocks tumor-induced angiogenesis (80).”
- ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. (2002, background): “(15) also showed that ZD1839 inhibits tumor cell synthesis of tumor growth factor and of the proangiogenic growth factors VEGF and bFGF.”
- ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. (2002, background): “Nonetheless, it is still feasible that inhibition of EGFR signaling could also contribute to an antiangiogenic effect in an EGFR-dependent tumor, from inhibition of direct EGF-induced angiogenesis and/or EGF-induced VEGF expression by tumor cells (65, 69).”